News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
356,890 Results
Type
Article (20318)
Company Profile (88)
Press Release (336466)
Multimedia
Podcasts (54)
Webinars (6)
Section
Business (89732)
Career Advice (1351)
Deals (17644)
Drug Delivery (80)
Drug Development (61641)
Employer Resources (62)
FDA (9292)
Job Trends (7591)
News (175509)
Policy (15301)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (1)
2027 Pharm Country Standard (3)
Academia (1241)
Academic (1)
Accelerated approval (41)
Adcomms (18)
Allergies (134)
Alliances (17888)
ALS (154)
Alzheimer's disease (1265)
Antibody-drug conjugate (ADC) (338)
Approvals (9706)
Artificial intelligence (315)
Autoimmune disease (214)
Automation (21)
Bankruptcy (139)
Best Places to Work (6369)
BIOSECURE Act (8)
Biosimilars (154)
Biotechnology (55)
Bladder cancer (161)
Brain cancer (55)
Breast cancer (665)
Cancer (4612)
Cardiovascular disease (370)
Career advice (1082)
Career pathing (23)
CAR-T (222)
CDC (21)
Celiac Disease (2)
Cell therapy (575)
Cervical cancer (33)
Clinical research (55726)
Collaboration (1095)
Company closure (2)
Compensation (575)
Complete response letters (45)
COVID-19 (2325)
CRISPR (54)
C-suite (416)
Cystic fibrosis (109)
Data (6598)
Decentralized trials (1)
Denatured (5)
Depression (115)
Dermatology (63)
Diabetes (509)
Diagnostics (3665)
Digital health (25)
Diversity (3)
Diversity, equity & inclusion (8)
Drug discovery (178)
Drug pricing (100)
Drug shortages (23)
Duchenne muscular dystrophy (194)
Earnings (57388)
Editorial (33)
Employer branding (11)
Employer resources (54)
Events (58374)
Executive appointments (376)
FDA (12088)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (23)
Funding (1018)
Gene editing (128)
Generative AI (24)
Gene therapy (473)
GLP-1 (958)
Government (2537)
Grass and pollen (6)
Guidances (378)
Healthcare (9736)
HIV (67)
Huntington's disease (42)
IgA nephropathy (83)
Immunology and inflammation (228)
Immuno-oncology (72)
Indications (160)
Infectious disease (2554)
Inflammatory bowel disease (159)
Inflation Reduction Act (5)
Influenza (101)
Intellectual property (178)
Interviews (249)
IPO (10274)
IRA (22)
Job creations (1478)
Job search strategy (921)
JPM (41)
Kidney cancer (20)
Labor market (61)
Layoffs (312)
Leadership (26)
Legal (2502)
Liver cancer (71)
Longevity (13)
Lung cancer (646)
Lymphoma (377)
Machine learning (22)
Management (17)
Manufacturing (484)
MASH (169)
Medical device (6637)
Medtech (6692)
Mergers & acquisitions (8107)
Metabolic disorders (1287)
mRNA (118)
Multiple sclerosis (154)
NASH (18)
Neurodegenerative disease (313)
Neuropsychiatric disorders (82)
Neuroscience (2399)
Neurotech (1)
NextGen: Class of 2026 (2667)
Non-profit (1867)
Now hiring (22)
Obesity (620)
Opinion (132)
Ovarian cancer (174)
Pain (181)
Pancreatic cancer (225)
Parkinson's disease (291)
Partnered (18)
Patents (317)
Patient recruitment (503)
Peanut (50)
People (16462)
Pharmaceutical (24)
Pharmacy benefit managers (10)
Phase 1 (15868)
Phase 2 (27469)
Phase 3 (17978)
Pipeline (6810)
Policy (114)
Postmarket research (1589)
Preclinical (5352)
Press Release (30)
Prostate cancer (239)
Psychedelics (42)
Radiopharmaceuticals (208)
Rare diseases (774)
Real estate (1774)
Recruiting (31)
Regulatory (14073)
Reports (38)
Research institute (1214)
Resumes & cover letters (260)
Rett syndrome (34)
RNA editing (12)
RSV (63)
Schizophrenia (147)
Series A (155)
Series B (123)
Service/supplier (5)
Sickle cell disease (85)
Special edition (22)
Spinal muscular atrophy (150)
Sponsored (32)
Startups (1371)
State (2)
Stomach cancer (18)
Supply chain (60)
Tariffs (44)
The Weekly (49)
Vaccines (761)
Venture capital (46)
Weight loss (413)
Women's health (71)
Worklife (13)
Date
Today (119)
Last 7 days (684)
Last 30 days (2193)
Last 365 days (20518)
2026 (7777)
2025 (20491)
2024 (22006)
2023 (24442)
2022 (29983)
2021 (32059)
2020 (30533)
2019 (22701)
2018 (17293)
2017 (17519)
2016 (15333)
2015 (18689)
2014 (13379)
2013 (9816)
2012 (10616)
2011 (11095)
2010 (9732)
Location
Africa (421)
Alabama (52)
Alaska (1)
Arizona (134)
Arkansas (5)
Asia (23126)
Australia (4161)
California (8485)
Canada (2396)
China (1012)
Colorado (330)
Connecticut (421)
Delaware (269)
Europe (51880)
Florida (1167)
Georgia (282)
Hawaii (2)
Idaho (29)
Illinois (561)
India (54)
Indiana (379)
Iowa (15)
Japan (396)
Kansas (62)
Kentucky (36)
Louisiana (28)
Maine (43)
Maryland (968)
Massachusetts (6105)
Michigan (164)
Minnesota (365)
Mississippi (6)
Missouri (80)
Montana (17)
Nebraska (7)
Nevada (89)
New Hampshire (48)
New Jersey (2466)
New Mexico (4)
New York (2362)
North Carolina (878)
North Dakota (3)
Northern California (4232)
Ohio (200)
Oklahoma (3)
Oregon (20)
Pennsylvania (1599)
Puerto Rico (25)
Rhode Island (20)
South America (582)
South Carolina (25)
Southern California (3486)
Tennessee (91)
Texas (1376)
United States (29352)
Utah (205)
Vermont (1)
Virginia (179)
Washington D.C. (39)
Washington State (660)
West Virginia (1)
Wisconsin (65)
356,890 Results for "2".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
ALS
QurAlis’ Phase 2 data bolster case for genetic approach to sporadic ALS
Biogen’s Qalsody won FDA approval in 2023 to treat a rare, genetic form of amyotrophic lateral sclerosis. On Tuesday, QurAlis presented interim Phase 2 data showing the potential of a similar drug to more broadly treat the neurodegenerative disease.
May 5, 2026
·
4 min read
·
Heather McKenzie
Funding
Revolution doubles stock offering target to $2B following pancreatic cancer win
After Revolution Medicines’ drug candidate doubled survival in a Phase 3 pancreatic cancer study, the biotech is hoping to attract more investor money, with new plans for a $2 billion stock and debt offering.
April 16, 2026
·
1 min read
·
Tristan Manalac
Cardiovascular disease
Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout
While tonlamarsen missed one of two co-primary endpoints, Kardigan says the drug has shown a clinically meaningful effect on blood pressure, supporting advancement into Phase 2b.
March 30, 2026
·
2 min read
·
Annalee Armstrong
Press Releases
Yaqrit Phase 2a data, clinical consensus boost YAQ007 and YAQ006 in Hepatic Encephalopathy
• Strong global consensus on measurement and role of ammonia in Hepatic Encephalopathy (HE) • Phase 2a results of YAQ007 (oral OPA) show ammonia reduction • Utility of rifaximin in HE defined more narrowly
April 20, 2026
·
1 min read
Breast cancer
Novartis Buys Breast Cancer Drug for $2B to Keep Up With Myriad Rivals
Aside from the $2 billion upfront payment, Novartis is also putting up to $1 billion on the line in milestones for Synnovation Therapeutics’ pan-mutant-selective PI3Kα blocker.
March 20, 2026
·
2 min read
·
Tristan Manalac
Press Releases
PHERGain and PHERGain-2 advance therapeutic de-escalation in early HER2-positive breast cancer in selected patients
May 7, 2026
·
5 min read
Mergers & acquisitions
UCB captures Candid in $2.2B autoimmune deal as pharma’s M&A train chugs along
Candid Therapeutics follows closely behind Neurona Therapeutics, which UCB acquired in mid-April in a potential $1.15 billion deal.
May 4, 2026
·
2 min read
·
Tristan Manalac
Press Releases
OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET
• Regulatory feedback recent from April 2026 EU EMA and Australian TGA meetings • Remaining Q2-2026 regulatory meetings include two U.S. FDA meetings and one UK MHRA meeting, in addition to follow-up meetings with EU EMA and Australian TGA
April 27, 2026
·
5 min read
Press Releases
Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer
May 5, 2026
·
8 min read
Press Releases
Avenzo Therapeutics Advances the Combination of CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) in Ongoing Phase 1/2 ORION-1 Study in HR+/HER2- Breast Cancer
April 28, 2026
·
3 min read
1 of 35,689
Next
